Abstract
Carbosilane ruthenium(ii) dendrimers have been complexed with conventional anti-cancer drugs. Due to its features, the presence of ruthenium within a dendrimer structure improves the anti-cancer properties of nanocomplexes containing 5-flurouracyl, methotrexate and doxorubicin. These dendrimers could be promising carriers of anti-cancer medicines. Ruthenium dendrimers that are positively charged can also enhance the cytotoxicity to cancer cells; moreover, they can form stable complexes with drugs. Results indicate that ruthenium dendrimers combined with doxorubicin and methotrexate significantly reduced the viability of leukaemia 1301 and HL-60 cancer cells.
MeSH terms
-
Anisotropy
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / chemistry
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Dendrimers / administration & dosage*
-
Dendrimers / chemistry
-
Doxorubicin / administration & dosage*
-
Doxorubicin / chemistry
-
Drug Combinations
-
Erythrocyte Membrane / drug effects
-
Fluorescence
-
Humans
-
Leukemia
-
Methotrexate / administration & dosage*
-
Methotrexate / chemistry
-
Nanostructures / administration & dosage*
-
Nanostructures / chemistry
-
Ruthenium / administration & dosage*
-
Ruthenium / chemistry
-
Silanes / administration & dosage*
-
Silanes / chemistry
Substances
-
Antineoplastic Agents
-
Dendrimers
-
Drug Combinations
-
Silanes
-
carbosilane
-
Ruthenium
-
Doxorubicin
-
Methotrexate